PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans

What Was Tested

This randomized controlled trial paper looks at Peptide YY and Oxyntomodulin.

Peptide YY(3-36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal.

The aim of the current study was to investigate whether the anorectic effects of PYY(3-36) and oxyntomodulin can be additive.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Twelve overweight or obese human volunteers underwent a randomized, double-blinded, placebo-controlled study.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

As a double-blind Peptide YY study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Peptide YY group a baseline to be compared against.

An ad libitum test meal was used to measure energy intake during intravenous infusions of either PYY(3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.

What Was Measured

The subject headings attached to it are Drug Interactions, Eating, Energy Intake, Obesity, Overweight, Oxyntomodulin and Patient Selection.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptide YY and Oxyntomodulin.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Diabetes), a journal based in United States.

More context: the Peptide YY compound page and the Oxyntomodulin compound page, all human trials.